JCT  Vol.6 No.13 , December 2015
Use of Initial Modified RECIST Tumor Response Evaluation Criteria for Predicting Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization with Drug-Eluting Beads
Abstract: Introduction: Transarterial chemoembolization (TACE) reduces tumor growth and increases survival in patients with hepatocellular carcinoma (HCC). Drug-eluting beads (DEB) deliver slow-release chemotherapy and reduce systemic toxicity during TACE. This study correlated initial tumor response according to modified RECIST (mRECIST) criteria and 1-year survival in patients with HCC treated with TACE-DEB, and identified predictors of tumor response. Methods: Fifty-two patients with HCC received TACE-DEB loaded with doxorubicin 75 mg during a 6-month period. Tumor response was evaluated 1 month after the procedure according to mRECIST criteria. Results: Most patients were cirrhotic and etiology of liver disease was hepatitis C in 26/52 (50%). Similar numbers of patients had Barcelona Clinic Liver Cancer (BCLC) A and BCLC B disease. Most patients had one nodule (66%). Complete response (CR) was achieved in 12/52 (23%), partial response in 19/52 (37%), stable disease in 4/52 (8%) and progressive disease in 17/52 (32%). Largest HCC ≤58 mm and BCLC stage A were associated with CR. The 1-year survival was 74%, with survival rates of 95% and 56% in the BCLC A and B groups, respectively. Variables reflecting tumor extension were associated with better survival. CR according to mRECIST criteria was a predictor of better 1-year survival (100% vs. 64%, P < 0.05). Conclusion: BCLC A and CR according to mRECIST criteria predict improved 1-year survival in patients with HCC treated with TACE-DEB. Further studies are needed to evaluate other predictors of survival and to determine if tumor response predicts long-term survival.
Cite this paper: Queiroz, N. , Kikuchi, L. , Bezerra, R. , Alencar, R. , Chagas, A. , Tani, C. , Diniz, M. , Santos, A. , Moreira, A. , Rocha, M. , D’Albuquerque, L. , Carnevale, F. and Carrilho, F. (2015) Use of Initial Modified RECIST Tumor Response Evaluation Criteria for Predicting Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization with Drug-Eluting Beads. Journal of Cancer Therapy, 6, 1115-1123. doi: 10.4236/jct.2015.613121.

[1]   Kang, H., Lee, H.Y., Lee, K.S. and Kim, J.-H. (2012) Imaging-Based Tumor Treatment Response Evaluation: Review of Conventional, New, and Emerging Concepts. Korean Journal of Radiology, 13, 371-390.

[2]   Gillmore, R., Stuart, S., Kirkwood, A., Hameeduddin, A., Woodward, N., Burroughs, A.K. and Meyer, T. (2011) EASL and mRECIST Responses Are Independent Prognostic Factors for Survival in Hepatocellular Cancer Patients Treated with Transarterial Embolization. Journal of Hepatology, 55, 1309-1316.

[3]   Bruix, J. and Sherman, M. (2011) Management of Hepatocellular Carcinoma: An Update. Hepatology, 53, 1020-1022.

[4]   Bruix, J., Sherman, M., Llovet, J.M., Beaugrand, M., Lencioni, R., Burroughs, A.K., Christensen, E., Pagliaro, L., Colombo, M. and Rodés, J. (2001) Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. Journal of Hepatology, 35, 421-430.

[5]   Lammer, J., Malagari, K., Vogl, T., Pilleul, F., Denys, A., Watkinson, A., Pitton, M., Sergent, G., Pfammatter, T., Terraz, S., Benhamou, Y., Avajon, Y., Gruenberger, T., Pomoni, M., Langenberger, H., Schuchmann, M., Dumortier, J., Mueller, C., Chevallier, P. and Lencioni, R. (2010) Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. CardioVascular and Interventional Radiology, 33, 41-52.

[6]   Song, M.J., Chun, H.J., Song, D.S., Kim, H.Y., Yoo, S.H., Park, C.-H., Bae, S.H., Choi, J.Y., Chang, U.I., Yang, J.M., Lee, H.G. and Yoon, S.K. (2012) Comparative Study between Doxorubicin-Eluting Beads and Conventional Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma. Journal of Hepatology, 57, 1244-1250.

[7]   Lencioni, R. and Llovet, J.M. (2010) Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. Seminars in Liver Disease, 30, 52-60.

[8]   Huang, K., Zhou, Q., Wang, R., Cheng, D. and Ma, Y. (2014) Doxorubicin-Eluting Beads versus Conventional Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology, 29, 920-925.

[9]   Xie, Z.-B., Wang, X.-B., Peng, Y.-C., Zhu, S.-L., Ma, L., Xiang, B.-D., Gong, W.-F., Chen, J., You, X.-M., Jiang, J.-H., Li, L.-Q. and Zhong, J.-H. (2014) Systematic Review Comparing the Safety and Efficacy of Conventional and Drug-Eluting-Bead Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma. Hepatology Research, 45, 190-200.

[10]   Burrel, M., Reig, M., Forner, A., Barrufet, M., de Lope, C.R., Tremosini, S., Ayuso, C., Llovet, J.M., Real, M.I. and Bruix, J. (2012) Survival of Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolisation (TACE) Using Drug Eluting Beads. Implications for Clinical Practice and Trial Design. Journal of Hepatology, 56, 1330-1335.

[11]   Skowasch, M., Schneider, J., Otto, G., Weinmann, A., Woerns, M.A., Dueber, C. and Pitton, M.B. (2012) Midterm Follow-Up after DC-BEADTM-TACE of Hepatocellular Carcinoma (HCC). European Journal of Radiology, 81, 3857-3861.

[12]   Sala, M., Llovet, J.M., Vilana, R., Bianchi, L., Solé, M., Ayuso, C., Brú, C. and Bruix, J. (2004) Initial Response to Percutaneous Ablation Predicts Survival in Patients with Hepatocellular Carcinoma. Hepatology, 40, 1352-1360.

[13]   Schoenfeld, D. (1982) Partial Residuals for the Proportional Hazards Regression Model. Biometrika, 69, 239-241.

[14]   Zou, G. (2004) A Modified Poisson Regression Approach to Prospective Studies with Binary Data. American Journal of Epidemiology, 159, 702-706.

[15]   R Development Core Team (2014) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. R Foundation for Statistical Computing, Vienna.